Eli Lilly and Company (NYSE: LLY) experienced a modest decline in its share price on Friday, August 28, 2026, following the U.S. Food and Drug Administration's (FDA) approval of Mounjaro for a new cardiovascular indication. The stock fell 0.9% to $1,165.73, erasing approximately $9.8 billion in market capitalization. This muted reaction suggests that investors had largely anticipated the regulatory green light, reflecting the high expectations already embedded in Lilly's valuation.
The FDA's approval allows Mounjaro (tirzepatide) to be used to reduce the risk of cardiovascular death, heart attacks, and strokes in adults with type 2 diabetes who are at high risk for these events. This label expansion is significant, as it broadens the drug's therapeutic scope beyond glucose control and weight management, potentially enhancing its acceptance among insurers and physicians.
Mounjaro's commercial performance has been stellar, with second-quarter sales reaching approximately $9.9 billion, a 91% increase year-over-year. This figure represents about 43% of Lilly's total quarterly revenue of $22.97 billion. In the U.S. alone, Mounjaro generated $4.8 billion in sales, up 45% from the prior year, although robust demand was partially offset by lower realized prices.
The approval is underpinned by data from the SURPASS-CVOT study, which compared Mounjaro to Lilly's older GLP-1 drug, Trulicity (dulaglutide). The trial demonstrated an 8% relative reduction in major adverse cardiovascular events (MACE-3), with a hazard ratio of 0.92 (95.3% CI: 0.83–1.01). While this result met the noninferiority threshold, it did not achieve statistical superiority. However, a secondary analysis showed a 16% reduction in all-cause mortality, bolstering the overall clinical profile even though it was not the primary endpoint.
With this approval, Lilly closes a competitive gap with Novo Nordisk (NYSE: NVO), which already holds cardiovascular indications for its drugs Wegovy and Rybelsus. The expanded label for Mounjaro strengthens Lilly's position in the diabetes and obesity market, where tirzepatide-based products (Mounjaro and Zepbound) now account for nearly 64% of the company's total revenue. Zepbound contributed an additional $4.9 billion in U.S. sales during the quarter.
Wall Street remains optimistic about Lilly's prospects. According to Google Finance data, the stock has 18 buy ratings and 2 hold ratings, with an average price target of $1,391.61, implying upside of about 19% from current levels. However, risks persist, including potential price erosion, supply constraints, and competitive pressures. The drug's label also carries warnings for thyroid C-cell tumors and pancreatitis.
The approval is a pivotal moment for Lilly, as it expands an already dominant franchise. The company's ability to convert this label expansion into increased prescriptions and sustained net pricing will be critical in determining whether earnings estimates continue to rise. As the market digests the news, all eyes will be on prescription trends and payer coverage decisions in the coming months.
